Carmell Short Long Term Debt Total from 2010 to 2024

CTCXW Stock   0.06  0  1.96%   
Carmell Therapeutics Short and Long Term Debt Total yearly trend continues to be fairly stable with very little volatility. Short and Long Term Debt Total is likely to outpace its year average in 2024. During the period from 2010 to 2024, Carmell Therapeutics Short and Long Term Debt Total regression line of quarterly data had mean square error of 4.1 T and geometric mean of  7,767,078. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
2010-12-31
Previous Quarter
2.1 M
Current Value
4.1 M
Quarterly Volatility
2.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Carmell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Carmell Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 162.5 K or Interest Expense of 844.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.78. Carmell financial statements analysis is a perfect complement when working with Carmell Therapeutics Valuation or Volatility modules.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

Latest Carmell Therapeutics' Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of Carmell Therapeutics over the last few years. It is Carmell Therapeutics' Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Carmell Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Slightly volatile
   Short Long Term Debt Total   
       Timeline  

Carmell Short Long Term Debt Total Regression Statistics

Arithmetic Mean8,417,154
Geometric Mean7,767,078
Coefficient Of Variation31.58
Mean Deviation2,030,832
Median9,686,424
Standard Deviation2,658,160
Sample Variance7.1T
Range7.5M
R-Value(0.68)
Mean Square Error4.1T
R-Squared0.47
Significance0
Slope(406,502)
Total Sum of Squares98.9T

Carmell Short Long Term Debt Total History

20244.1 M
20232.1 M
20223.7 M

About Carmell Therapeutics Financial Statements

Carmell Therapeutics investors use historical fundamental indicators, such as Carmell Therapeutics' Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Carmell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short and Long Term Debt Total2.1 M4.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Carmell Stock Analysis

When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.